Adherent Cells from Adipose or Placenta Tissues and Use Thereof in Therapy
A patent family: one line of work, grouped by real continuity rather than by a technology label
inferred from titles. 2 of these applications claim priority to application PCT/IL2008/001185, filed Sep 2, 2008. A shared origin can cover several different claimed inventions, which is why members here may not share a title. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
| Patent | Title | Holder | Status | Expires | Time remaining | Confidence |
|---|---|---|---|---|---|---|
| US 9,517,248 | Adherent Cells from Adipose or Placenta Tissues and Use Thereof in Therapy In force · Low confidence | Pluri Biotech Ltd. | In force | Low confidence | ||
| US 8,529,888 | Adherent Cells from Adipose or Placenta Tissues and Use Thereof in Therapy In force · High confidence | Pluri Biotech Ltd. | In force | High confidence | ||
| Application 17/817,488 | Adherent Cells from Adipose or Placenta Tissues and Use Thereof in Therapy Abandoned Abandoned Sep 29, 2025 | Pluri Biotech Ltd. | Abandoned | Abandoned Sep 29, 2025 |
3 of 3 records shown. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
2 of these are in force and held by Pluri Biotech Ltd..
Updated Nov 17, 2026 · includes USPTO assignment data published Nov 16, 2026, status data published Nov 17, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.